UNCY Q3 EPS Estimate Boosted by Brookline Capital Management

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at Brookline Capital Management boosted their Q3 2025 EPS estimates for Unicycive Therapeutics in a research report issued to clients and investors on Tuesday, June 10th. Brookline Capital Management analyst K. Raja now forecasts that the company will post earnings of ($0.05) per share for the quarter, up from their prior estimate of ($0.07). The consensus estimate for Unicycive Therapeutics' current full-year earnings is ($0.23) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics' Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.15) EPS, FY2026 earnings at ($0.08) EPS, FY2027 earnings at $0.63 EPS, FY2028 earnings at $0.85 EPS and FY2029 earnings at $1.01 EPS.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.09.

UNCY has been the topic of several other reports. Guggenheim initiated coverage on Unicycive Therapeutics in a research note on Monday, April 21st. They set a "buy" rating and a $6.00 price objective on the stock. HC Wainwright raised Unicycive Therapeutics to a "strong-buy" rating and set a $9.00 price objective for the company in a report on Tuesday, May 27th.

Unicycive Therapeutics Trading Up 1.3%

NASDAQ:UNCY traded up $0.01 on Thursday, reaching $0.64. 4,175,719 shares of the stock traded hands, compared to its average volume of 1,938,599. The firm has a market capitalization of $76.95 million, a price-to-earnings ratio of -0.66 and a beta of 2.01. Unicycive Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.10. The company's 50 day moving average is $0.61 and its 200-day moving average is $0.63.

Institutional Investors Weigh In On Unicycive Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp boosted its position in shares of Unicycive Therapeutics by 142.4% during the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company's stock valued at $46,000 after buying an additional 34,183 shares during the last quarter. Nantahala Capital Management LLC raised its stake in Unicycive Therapeutics by 268.5% during the 4th quarter. Nantahala Capital Management LLC now owns 10,391,994 shares of the company's stock valued at $8,253,000 after purchasing an additional 7,571,636 shares during the period. Geode Capital Management LLC raised its stake in Unicycive Therapeutics by 30.3% during the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock valued at $417,000 after purchasing an additional 122,089 shares during the period. XTX Topco Ltd grew its holdings in Unicycive Therapeutics by 142.2% during the 4th quarter. XTX Topco Ltd now owns 171,463 shares of the company's stock valued at $136,000 after buying an additional 100,679 shares in the last quarter. Finally, Vivo Capital LLC boosted its holdings in shares of Unicycive Therapeutics by 123.0% in the 4th quarter. Vivo Capital LLC now owns 9,970,152 shares of the company's stock worth $7,918,000 after purchasing an additional 5,500,000 shares during the period. 40.42% of the stock is owned by hedge funds and other institutional investors.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.